Aktiechat - investeringstips

	2/3 17:19 af Jan Van de Winkel	We saw IMS data at around 26 mn USD for January which is well above the 16 mn USD we saw for December.....
	2/3 17:18 af investor1989	You said on the conference call weekly uptake on Dara sales from IMS was up pretty well every week . Now 3 weeks later, are the data still the same with nice uptake?
	2/3 17:14 af Jan Van de Winkel	The strategy is to make daratumumab the solid backbone regimen for treatment of MM. In that context, it could be combined with a number of PIs and IMiDs...!
	2/3 17:13 af Sukkeralf	Jan how do you think Janssen will position Daratumumab/Vecade against Daratumumab/Kyprolis or Daratumumab/Ninlaro in the comming years?
	2/3 17:12 af Jan Van de Winkel	Yes, correct.
	2/3 17:12 af Sukkeralf	If Daratumumab interim data for Pollux and/or Castor are good enough for filing - then it´s a sBLA right ?
	2/3 17:12 af Jan Van de Winkel	re the three frontline studies in MM, they are all recruiting well.
	2/3 17:11 af Jan Van de Winkel	Furthermore...both Velcade and Revlimid will become generic in the coming years. So likely resulting in less costly combi therapies. ....
	2/3 17:11 af Jan Van de Winkel	The US price for the first year is 135,000 USD and for the second year is 76,000 USD.
	2/3 17:10 af investor1989	The Castor and Pollux studies recruited patients with rocket speed. Can you tell how recruitment are going in the two front line studies?
	2/3 17:10 af Jan Van de Winkel	Janssen have priced very competitively in the US. DARZALEX is slightly lower than the competing drugs in the first year, however, it becomes much cheaper in the second year of use as there are fewer doses.
	2/3 17:09 af MUFC Oberanven	Question about pricing of Castor and Pollux when they hit the market: As I see it, it will be very expensive products, because you combine 3 products who each are very expensive. Should we expect prices in the area of USD 300t per year? How are the prices compared to other combo products?
	2/3 17:08 af Jan Van de Winkel	If the data at the interims is positive and hits the primary endpoint, the next steps for Janssen will be to file in 2016 leading to a broader label. Second line is of course, a much larger market than the last line fourth therapy.
	2/3 17:07 af Helge Larsen/PI-redaktør	To what extent will such a successful outcome of the Phase 3 studies Pollux and Castor affect the sale of Darzalex? Somewhere I saw you quoted, for saying that it will “increase sales dramatically in the United States”. It the quote is correct, what do you consider “a dramatic increase”?
	2/3 17:05 af Jan Van de Winkel	It will of course take time in Europe to negotiate pricing on a country to country basis, however we anticipate a rapid launch in some countries such as Germany following approval.
	2/3 17:05 af Helge Larsen/PI-redaktør	As for the European market - in case of an approval of Darzalex - will we then experience an equally rapid roll out similar to the one in USA? And: How do you estimate the potential for the sale in Europe in percents compared with USA?
	2/3 17:04 af Jan Van de Winkel	and we hope to see further data with tisotumab vedotin in the second half of this year as well as initiation of clinical work with HuMax-AXL-ADC.
	2/3 17:03 af Jan Van de Winkel	Furthermore, we hope to see initiation of clinical studies in MS by our partner Novartis with subcue ofatumumab....
	2/3 17:03 af Jan Van de Winkel	we expect to get interim results for two key phase three combination studies in second line MM. And if positive we hope to file in both the US and EU....
	2/3 17:02 af Jan Van de Winkel	Highlights for 2016 - we are hoping for an approval in Europe for DARZALEX....
	2/3 17:01 af Jan Van de Winkel	Highlights for this 2015: DARZALEX approval in November was of course the biggest highlight of the year....
	2/3 17:01 af Helge Larsen/PI-redaktør	About your goals for 2016: Which do you consider the most important for Genmab?
	2/3 17:01 af Jan Van de Winkel	highest ever operating income at 730 mn DKK. Up 465 on 2014. Cash position 3.5 bn at the end of the year.
	2/3 17:00 af Jan Van de Winkel	at over 1.1bn DKK, flat expenses for the fifth year in a row...

	2/3 17:00 af Jan Van de Winkel	Let's start with the key figures (from David). Highest ever revenue....
	2/3 16:59 af Helge Larsen/PI-redaktør	Great. First of all let me just congratulate on the great results for 2015 . Can you give us a short-term update on key figures and important events in quarter 4 and for 2015.
	2/3 16:59 af Jan Van de Winkel	Thank you, looking forward to some good questions as always.
	2/3 16:58 af Helge Larsen/PI-redaktør	Welcome to CEO Jan van de Winkel and CFO David Eatwell to ProInvestors Q & A. We are very glad to have you back here on ProInvestor.com and ready to answer questions from our investors.
	2/3 16:57 af Jan Van de Winkel	Looking forward to speaking with you all.
	2/3 16:57 af Jan Van de Winkel	Yes I am here with David Eatwell Genmab's CFO.
	2/3 16:57 af Helge Larsen/PI-redaktør	Are you with us here online Jan?
	2/3 16:51 af Helge Larsen/PI-redaktør	In 10 minutes we begin the online Q&A with Genmab.